Male hypogonadism in the primary care clinic

Primary Care - Clinics in Office Practice

Volumn 30, Issue 4, 2003, Pages 743-763

  Grant, Nicole N ^a   Anawalt, Bradley D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CIMETIDINE; CORTICOSTEROID; FINASTERIDE; FLUTAMIDE; FOLLITROPIN; GESTAGEN; GONADORELIN; INHIBIN B; KETOCONAZOLE; LEUPRORELIN; LUTEINIZING HORMONE; MEGESTROL ACETATE; METOCLOPRAMIDE; OPIATE; PSYCHOTROPIC AGENT; SEX HORMONE BINDING GLOBULIN; SPIRONOLACTONE; TESTODERM TTS; TESTOSTERONE; TESTOSTERONE CIPIONATE; TESTOSTERONE ENANTATE; TESTOSTERONE ESTER;

ALGORITHM; CLINICAL EXAMINATION; CORONARY RISK; DRUG COST; DRUG SAFETY; GLUCOSE TOLERANCE; HORMONAL THERAPY; HUMAN; HYPERLIPIDEMIA; HYPOGONADISM; INJECTION PAIN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; RASH; REVIEW; TESTOSTERONE BLOOD LEVEL; TREATMENT PLANNING;

EID: 0345802812     PISSN: 00954543     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0095-4543(03)00091-5     Document Type: Review

References (75)

1. Harman SM. Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001;86(2):724-31.
2. Matsumoto AM. Hormonal therapy of male hypogonadism. Endocrinol Metab Clin North Am 1994;23(4):857-75.
3. Amory JK, Anawalt BD, Paulsen CA, Bremner WJ. Klinfelter's syndrome. Lancet 2000;356(9226):333-5.
4. Hammond GL, NiskerJA, Jones LA, Siiteri PK. Estimation of the percentage of free steroid in undiluted serum by centrifugal ultrafiltration-dialysis. J Biol Chem 1980:255(11):5023-6.
5. Pardridge WM. Selective delivery of sex steroid hormones to tissues in vivo by albumin and by sex hormone-binding globulin. Ann NY Acad Sci 1988;538:173-92.
6. Plymate SR III. Which testosterone assay should be used in older men? J Clin Endocrinol Metab 1998:83(10):3436a-8.
7. Cumming DC. Wall SR. Non-sex hormone-binding globulin-bound testosterone as a marker for hyperandrogenism. J Clin Endocrinol Metab 1985;61(5):873-6.
8. Wheeler MJ. The determination of bio-available testosterone. Ann Clin Biochem 1995: 32(Pt 4):345-57.
9. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84(10):3666-72.
10. McCann DS, Kirkish LS. Evaluation of free testosterone in serum. J Clin Immunoassay 1985;8(4):234-6.
11. Rosner W. Errors in the measurement of plasma free testosterone. J Clin Endocrinol Metab 1997:82(6):2014-5.
12. Winters SJ, Kelley DE, Goodpaster B. The analog free testosterone assay: are the results in men clinically useful? Clin Chem 1998;44(10):2178-82.
13. Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002;87(2):589-98.
14. Bremner WJ, Vitiello MV, Prinz PN. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab 1983;56(6):1278-81.
15. Smith KW, Feldman HA, McKinlay JB. Construction and field validation of a self-administered screener for testosterone deficiency (hypogonadism) in ageing men. Clin Endocrinol (Oxf) 2000;53(6):703-11.
16. Matsumoto AM. Andropause: clinical implications of the decline in serum testosterone levels with aging in men. J Gerontol A Biol Sci Med Sci 2002;57(2):M76-99.
17. Powell LW, George DK, McDonnell SM, Kowdley KV. Diagnosis of hemochromatosis. Ann Intern Med 1998;129(11):925-31.
18. McDonnell SM. Phatak PD, Felitti V, Hover A, McLaren GD. Screening for hemochromatosis in primary care settings. Ann Intern Med 1998;129(11):962-70.
19. Edwards CQ, Kushner JP. Screening for hemochromatosis. N Engl J Med 1993;328(22): 1616-20.
20. Molitch ME. Disorders of prolactin secretion. Endocrinol Metab Clin North A 2001; 30(3):585-610.
21. Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000;85(8):2670-7.
22. Bhasin S, Storer TW, Berman N, et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 1997;82(2):407-13.
23. Finkelstein JS, Klibanski A, Neer RM, et al. Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 1989; 69(4):776-83.
24. Greenspan SL, Oppenheim DS, Klibanski A. Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism. Ann Intern Med 1989;110(7):526-31.
25. Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996;81(12):4358-65.
26. Kubler A, Schulz G, Cordes U, Beyer J, Krause U. The influence of testosterone substitution on bone mineral density in patients with Klinefelter's syndrome. Exp Clin Endocrinol 1992;100(3):129-32.
27. Leifke E, Korner HC, Link TM, Behre HM, Peters PE, Nieschlag E. Effects of testosterone replacement therapy on cortical and trabecular bone mineral density, vertebral body area and paraspinal muscle area in hypogonadal men. Eur J Endocrinol 1998; 138(1): 51-8.
28. Wang C, Eyre DR, Clark R, et al. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men-a clinical research center study. J Clin Endocrinol Metab 1996; 81(10):3654-62.
29. Wang C, Swedloff RS, Iranmanesh A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group. J Clin Endocrinol Metab 2000;85(8):2839-53.
30. Wang C, Alexander G, Berman N, et al. Testosterone replacement therapy improves mood in hypogonadal men-a clinical research center study. J Clin Endocrinol Metab 1996; 81(10):3578-83.
31. Morley JE, Kaiser FE, Perry 3rd HM, et al. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 1997;46(4):410-3.
32. van den Beld AW, de Jong FH, Grobbee DE, Pols HA, Lamberts SW. Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab 2000: 85(9):3276-82.
33. Khosla S, Melton 3rd LJ, Atkinson EJ, O'Fallon WM, Klee GG, Riggs BL. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 1998;83(7): 2266-74.
34. Greendale GA, Edelstein S, Barrett-Connor E. Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study. J Bone Miner Res 1997; 12(11):1833-43.
35. Sih R, Morley JE, Kaiser FE, Perry 3rd HM, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 1997;82(6):1661-7.
36. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999;84(6):1966-72.
37. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 1999;84(8):2647-53.
38. Tenover JL. Testosterone for all? Paper presented at the 80th Meeting of the Endocrine Society. New Orleans, LA, 1998.
39. Hajjar RR, Kaiser FE, Morley JE. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab 1997;82(11):3793-6.
40. Morley JE, Perry HM III, Kaiser FE, et al. Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc 1993;41(2):149-52.
41. Snyder PJ, Lawrence DA. Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab 1980;51(6):1335-9.
42. Nankin HR. Hormone kinetics after intramuscular testosterone cypionate. Fertil Steril 1987;47(6):1004-9.
43. Mackey MA, Conway AJ, Handelsman DJ. Tolerability of intramuscular injections of testosterone ester in oil vehicle. Hum Reprod 1995; 10(4):862-5.
44. J Amory JK, Matsumoto AM. The therapeutic potential of testosterone patches. Exp Opin Invest Drugs 1998;7(12):1977-85.
45. Arver S, Dobs AS, Meikle AW, et al. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men. Clin Endocrinol (Oxf) 1997;47(6):727-37.
46. Findlay JC, Place V, Snyder PJ. Treatment of primary hypogonadism in men by the transdermal administration of testosterone. J Clin Endocrinol Metab 1989;68(2):369-73.
47. Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 1999;84(10):3469-78.
48. Jordan WP Jr, Atkinson LE, Lai C. Comparison of the skin irritation potential of two testosterone transdermal systems: an investigational system and a marketed product. Clin Ther 1998;20(1):80-7.
49. Androgel. Med Lett Drugs Ther 2000;42(1080):49-51.
50. Swerdloff RS, Wang C, Cunningham G, et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab 2000;85(12):4500-10.
51. Matsumoto AM, Sandblom RE, Schoene RB, et al. Testosterone replacement in hypogonadal men: effects on obstructive sleep apnoea, respiratory drives, and sleep. Clin Endocrinol (Oxf) 1985;22(6):713-21.
52. Sandblom RE, Matsumoto AM, Schoene RB, et al. Obstructive sleep apnea syndrome induced by testosterone administration. N Engl J Med 1983;308(9):508-10.
53. Ismail M, Gomella LG. Current treatment of advanced prostate cancer. Tech Urol 1997;3(1):16-24.
54. Debruyne FM. Combined androgen blockade is the treatment of choice for patients with advanced prostate cancer: the argument for. Eur Urol 1996;29(Suppl 2):34-6.
55. Meikle AW, Arver S, Dobs AS, et al. Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system. Urology 1997;49(2):191-6.
56. Behre HM, Bohmeyer J, Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol (Oxf) 1994;40(3):341-9.
57. Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992;75(4):1092-8.
58. Proceedings of the Endocrine Society Andropause Consensus Conferences. Paper presented at Andropause Consensus. Los Angeles, CA. 2000-2001.
59. Screening for prostate cancer. American College of Physicians. Ann Intern Med 1997: 126(6):480-4.
60. Coley CM. Barry MJ, Fleming C, Fahs MC, Mulley AG. Early detection of prostate cancer. Part II: estimating the risks, benefits, and costs. American College of Physicians. Ann Intern Med 1997;126(6):468-79.
61. Castelli WP. Epidemiology of coronary heart disease: the Framingham study. Am J Med 1984;76(2A):4-12.
62. Whitsel EA, Boyko EJ, Matsumoto AM, Anawalt BD, Siscovick DS. Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. Am J Med 2001;111(4):261-9.
63. Bagatell CJ, Bremner WJ. The effects of aging and testosterone on lipids and cardiovascular risk. J Clin Endocrinol Metab 1998;83(10):3440-1.
64. Anawalt BD, Amory JK. Male hormonal contraceptives. Expert Opin Pharmacother 2001;2(9):1389-98.
65. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285(19):2486-97.
66. Alexandersen P, Haarbo J, Christiansen C. The relationship of natural androgens to coronary heart disease in males: a review. Atherosclerosis 1996;125(1):1-13.
67. Bagatell CJ, Bremner WJ. Androgen and progestagen effects on plasma lipids. Prog Cardiovasc Dis 1995;38(3):255-71.
68. von Eckardstein A, Kliesch S, Nieschlag E, Chirazi A, Assmann G, Behre HM. Suppression of endogenous testosterone in young men increases serum levels of high density lipoprotein subclass lipoprotein A-I and lipoprotein(a). J Clin Endocrinol Metab 1997;82(10):3367-72.
69. Haffner SM. Valdez RA, Mykkanen L, Stern MP, Katz MS. Decreased testosterone and dehydroepiandrosterone sulfate concentrations are associated with increased insulin and glucose concentrations in nondiabetic men. Metabolism 1994;43(5):599-603.
70. Haffner SM, Karhapaa P, Mykkanen L, Laakso M. Insulin resistance, body fat distribution, and sex hormones in men. Diabetes 1994;43(2):212-9.
71. Simon D, Preziosi P, Barrett-Connor E, et al. Interrelation between plasma testosterone and plasma insulin in healthy adult men: the Telecom Study. Diabetologia 1992;35(2):173-7.
72. Simon D, Charles MA, Nahoul K, et al. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: the Telecom Study. J Clin Endocrinol Metab 1997;82(2):682-5.
73. Webb CM, Adamson DL, de Zeigler D, Collins P. Effect of acute testosterone on myocardial ischemia in men with coronary artery disease. Am J Cardiol 1999;83(3): 437-9.
74. Webb CM, McNeill JG, Hayward CS, de Zeigler D, Collins P. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation 1999; 100(16):1690-6.
75. Pugh PJ, Jones RD. West JN, et al. Testosterone therapy for men with congestive heart failure. Presented at the Endocrine Society, San Francisco, June, 2002.